{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000005","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.965402+00:00","generated_at":"2026-05-28T03:16:43.726154+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix reports preliminary cash $609.6M; plans pivotal CLL trials for NX-5948 in 2025","bullets":["Preliminary cash and investments $609.6M as of Nov 30, 2024; runway into H1 2027.","NX-5948 achieved 75.5% ORR in CLL patients; FDA Fast Track and EMA PRIME designations.","Plans to initiate pivotal studies for NX-5948 in CLL in 2025; expand into WM and inflammatory indications.","Gilead exercised option on IRAK4 degrader; Sanofi collaboration extended; STAT6 degrader candidate nomination expected H1 2025.","Strengthened leadership: promoted Dr. O'Connor as CMO and Dr. Phiasivongsa as CTO; added Anil Kapur to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000005","json":"https://secwatch.observer/filing/0001549595-25-000005.json","markdown":"https://secwatch.observer/filing/0001549595-25-000005.md","text":"https://secwatch.observer/filing/0001549595-25-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000005/0001549595-25-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000005/nrix-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:16:43.726154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}